Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.

@article{Jayaram2005FailureOM,
  title={Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.},
  author={Lata Jayaram and Mylinh T Duong and Marcia Margaret Menezes Pizzichini and Emilio Pizzichini and Dennis Kamada and Ann E Efthimiadis and Frederick E. Hargreave},
  journal={The European respiratory journal},
  year={2005},
  volume={25 1},
  pages={41-6}
}
Sputum eosinophilia is a sensitive predictor of benefit from corticosteroid treatment. Montelukast is a cysteinyl leukotriene antagonist, which also reduces sputum and blood eosinophils. The present study examined the possibility that montelukast has an added eosinophil-lowering effect in subjects with asthma who are corticosteroid responsive but relatively corticosteroid resistant. A total of 14 clinically stable adults with asthma requiring minimum treatment with a high-dose inhaled steroid… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Does sputum cell counts alter asthma exacerbations? The LOMA study

MMM Pizzichini, L Jayaram, E Pizzichini
Am J Respir Crit Care Med • 2004

Adult asthma consensus guidelines update

C Lemiere, T Bai, M Balter
Can Respir J 2004; Suppl. A, • 2003

Cross-over trials in clinical research

S. Senn
2nd Edn. London, John Wiley & Sons Ltd, • 2002

Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthma subjects

Y Tohda, M Fujimura, H Taniguchi
Clin Exp Allergy • 2002

Similar Papers

Loading similar papers…